Analysts Offer Insights on Healthcare Companies: Alexion Pharmaceuticals (NASDAQ: ALXN) and Edwards Lifesciences (NYSE: EW)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alexion Pharmaceuticals (ALXNResearch Report) and Edwards Lifesciences (EWResearch Report).

Alexion Pharmaceuticals (ALXN)

In a report issued on May 6, Cory Kasimov from J.P. Morgan maintained a Buy rating on Alexion Pharmaceuticals, with a price target of $158.00. The company’s shares closed last Friday at $124.13, close to its 52-week high of $128.57.

According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 20.3% and a 55.8% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alexion Pharmaceuticals with a $146.75 average price target, a 21.3% upside from current levels. In a report issued on May 7, William Blair also assigned a Buy rating to the stock.

See today’s analyst top recommended stocks >>

Edwards Lifesciences (EW)

In a report issued on March 29, Marie Thibault from BTIG maintained a Hold rating on Edwards Lifesciences. The company’s shares closed last Friday at $85.33, close to its 52-week high of $87.79.

According to TipRanks.com, Thibault is a 5-star analyst with an average return of 30.1% and a 57.4% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Irhythm Technologies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Edwards Lifesciences with a $88.23 average price target, a 2.7% upside from current levels. In a report issued on April 28, Wells Fargo also downgraded the stock to Hold with a $76.66 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.